Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3427 with DOI

0 strong · 24 moderate · 10 weak

Compilations

12026-05-08T18:11:47.046Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

36last ruled 2026-06-04

1 awaiting a ruling

Issued documents

42026-10-19T20:32:00.719Z

notice · info card · emergency

Searches

202 with no results

queries and counts on the build

Claims checked

8065 supported

65 supported · 15 not

Correspondence

0received

consent field ships in Phase 4

Edges

262

derivations recorded for this entity

Complete over 34 sources, 1 compilation, and 36 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/flualprazolam/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-02srcIdentification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case
  3. 2026-10-02srcA fluorine turns a medicinal benzodiazepine into NPS: the case of flualprazolam
  4. 2026-10-02srcThe blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines
  5. 2026-10-02srcAn outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program
  6. 2026-10-02srcNo prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS)
  7. 2026-10-02srcFemoral blood concentrations of flualprazolam in 33 postmortem cases
  8. 2026-10-02srcSensitive detection and primary metabolism analysis of flualprazolam in blood
  9. 2026-10-02srcNon-targeted screening of alprazolam and flualprazolam metabolites in in vitro metabolism of different species by high-resolution mass spectrometry
  10. 2026-10-02srcDesigner benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam
  11. 2026-10-02srcClinical detoxification of bromazolam using diazepam: a case report
  12. 2026-10-02srcToxicokinetics and Analytical Toxicology of Flualprazolam: Metabolic Fate, Isozyme Mapping, Human Plasma Concentration and Main Urinary Excretion Products
  13. 2026-10-02srcBlood Concentrations of Designer Benzodiazepines: Relation to Impairment and Findings in Forensic Cases
  14. 2026-10-02srcFlualprazolam Blood Concentrations in 197 Forensic Investigation Cases
  15. 2026-10-02srcDevelopment and Validation of an LC-MS-MS Method for the Detection of 40 Benzodiazepines and Three Z-Drugs in Blood and Urine by Solid-Phase Extraction.
  16. 2026-10-02srcUrine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS
  17. 2026-10-02srcDriving Impairment Cases Involving Flualprazolam
  18. 2026-10-02srcFast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry
  19. 2026-10-02srcDeaths involving novel benzodiazepines in Victoria, Australia from 2018 to 2022
  20. 2026-10-02srcEmerging Characteristics of Isotonitazene-Involved Overdose Deaths: A Case-Control Study
  21. 2026-10-02srcThe surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San Francisco
  22. 2026-10-02srcRetrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis
  23. 2026-10-02srcChanges over time in novel benzodiazepines contributing to fatal overdoses in Victoria, Australia
  24. 2026-10-02srcThe Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction - A Narrative Review
  25. 2026-10-02srcFlualprazolam: Report of an Outbreak of a New Psychoactive Substance in Adolescents
  26. 2026-10-02srcNew Psychoactive Substances and receding COVID-19 pandemic: really going back to 'normal'?
  27. 2026-10-02srcRecent findings and advancements in the detection of designer benzodiazepines: a brief review
  28. 2026-10-02srcDesigner Benzodiazepines: A Review of Toxicology and Public Health Risks
  29. 2026-10-02srcFlualprazolam: Deadly drug found in fake Xanax tablets
  30. 2026-10-02srcCircular 006/2021: Control of Flualprazolam, Flunitrazolam and Norfludiazepam under the Misuse of Drugs Act 1971
  31. 2026-10-02srcUNODC: Falsified Xanax containing NPS flualprazolam and flubromazolam
  32. 2026-10-02srcUNODC Early Warning Advisory: Flualprazolam and Etizolam in postmortem and DUID cases
  33. 2026-10-02srcSchedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act (Final Rule)
  34. 2026-10-02srcSchedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (2022)
  35. 2026-10-02srcFlualprazolam (substance detail)
  36. 2026-09-04issueIssued emergency
  37. 2026-09-04issueIssued info_card
  38. 2026-09-04issueIssued notice
  39. 2026-07-03proposaldependence · taper
  40. 2026-06-04proposal33 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  41. 2026-06-04publicationPublication — backfill
  42. 2026-05-08revisionRevision 1
  43. 2026-05-08absenceSearched PubMed for "flualprazolam toxicology overdose death case report" — no results
  44. 2026-05-08absenceSearched ClinicalTrials.gov for "flualprazolam" — no results
  45. 2026-05-08genGeneration — pipeline-v5 · with 3 morepipeline-v5
  46. 2026-05-08rungeneration run

The same entries, as forms: six forms.